Antibody-based research applications are critical for biological discovery. Yet there are no
industry standards for comparing the performance of antibodies in various applications. We …

The etiology of idiopathic Parkinson's disease (iPD) is multifactorial, and both genetics and
environmental exposures are risk factors. While mutations in leucine-rich repeat kinase-2 …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors
for Parkinson's disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal …

Leucine-rich repeat kinase 2 (LRRK2) is one of the most promising targets for Parkinson's
disease. LRRK2-targeting strategies have primarily focused on type 1 kinase inhibitors …

Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial
Parkinson's disease and is also linked to its idiopathic form. LRRK2 has been proposed to …

We previously reported that Parkinson's disease (PD) kinase LRRK2 phosphorylates a
subset of Rab GTPases on a conserved residue in their switch-II domains (Steger et al …

Parkinson's disease-causing mutations in the leucine-rich repeat kinase 2 (LRRK2) gene
hyperactivate LRRK2 kinase activity and cause increased phosphorylation of Rab GTPases …

Cells respond to endolysosome damage by either repairing the damage or targeting
damaged endolysosomes for degradation via lysophagy. However, the signals regulating …

Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause
Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested …

Parkinson's disease predisposing LRRK2 kinase phosphorylates a group of Rab GTPase
proteins including Rab29, within the effector‐binding switch II motif. Previous work indicated …